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Background: The Multidrug Resistance Protein ABCC11/MRP8 is expressed in physiological barriers and tumor
breast tissues in which it secretes various substrates including cGMP (cyclic guanosine monophosphate) and
5FdUMP (5-fluoro-2′-deoxyuridine-5′-monophosphate), the active metabolite of the anticancer drug 5-FluoroUracil
(frequently included to anticancer therapy).
Previously, we described that ABCC11 high levels are associated to the estrogen receptor (ER) expression level in
breast tumors and in cell lines resistant to tamoxifen. Consequently, by lowering the intracellular concentration of
anticancer drugs, ABCC11 likely promotes a multidrug resistance (MDR) phenotype and decreases efficiency of
anticancer therapy of 5FdUMP. Since no experimental data about binding sites of ABCC11 substrate are available,
we decided to in silico localize putative substrate interaction sites of the nucleotide derivatives. Taking advantage of
molecular dynamics simulation, we also analysed their evolution under computational physiological conditions and
during the time.
Results: Since ABCC11 crystal structure is not resolved yet, we used the X-ray structures of the mouse mdr3
(homologous to human ABCB1) and of the bacterial homolog Sav1866 to generate two independent ABCC11
homology models in inward- and outward-facing conformations. Based on docking analyses, two putative binding
pockets, for cGMP and 5FdUMP, were localized in both inward- and outward-facing conformations. Furthermore,
based on our 3D models, and available biochemical data from homologous transporters, we identified several
residues, potentially critical in ABCC11 transport function. Additionally, molecular dynamics simulation on our
inward-facing model revealed for the first time conformation changes assumed to occur during transport process.
Conclusions: ABCC11 would present two binding sites for cGMP and for 5FdUMP. Substrates likely first bind at the
intracellular side of the transmembrane segment while ABCC11 is open forward the cytoplasm (inward-facing
conformation). Then, along with conformational changes, it would pass through ABCC11 and fix the second site
(close to the extracellular side), until the protein open itself to the extracellular space and allow substrate release.
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ABCC11/MRP8 (Multidrug Resistance protein 8) is a
human ABC (ATP-Binding Cassette) transporter that se-
cretes several endogenous substrates [1-3] including
cAMP, cGMP, as well as exogenous-derived molecules
[1-7] such as 5FdUMP (5′-fluoro-2′-deoxyuridine mo-
nophosphate), the active metabolite of 5-FluoroUracil,
methotrexate and aracytine. ABCC11 is expressed in vari-
ous tissues such as physiological barriers, suggesting a role
in body detoxification [3,8,9]. Its expression was asso-
ciated with a decrease of the clinical response to breast
tumor chemotherapy [10] and with a low probability of
survival in acute myeloid leukemia [7]. Furthermore,
ABCC11 is overexpressed in estrogen receptor-positive
cell lines resistant to tamoxifen [5] and in ERBB2-
overexpressing breast tumors [11]. By decreasing re-
tention of anticancer agent in cells, ABCC11 contributes
to a multidrug resistance (MDR) phenotype leading to cell
resistance to a broad range of anticancer agents.
Transport of cGMP by ABCC11 was largely described
by Guo et al. in 2003. They compared the cGMP intra-
cellular contents of ABCC11 overexpressing cells to
their counterpart (cells transfected with empty vector).
Only, the ABCC11 positive cells could extrude cGMP
under stimulation by SIN-1A. Additionally, they de-
scribed 5FdUMP transport by ABCC11 in inside-out
membrane vesicles. Vesicles bearing high levels of
ABCC11 showed an increased accumulation of 5FdUMP
and allow to conclude that 5FdUMP is an ABCC11 sub-
strate. Nevertheless, no pharmacokinetic study was un-







Figure 1 Mouse ABCB1- and Sav1866-based models of ABCC11 respe
Extracellular Loop; TM: Transmembrane segment; ICL: Intracellular Loop; MSvalues) neither for cGMP, nor for 5FdUMP. For the
ABCC4 homolog the Km of cGMP was 180 ± 20 μM [12].
ABCC11 is predicted to contain two Membrane-
Spanning Domains (MSDs) and two Nucleotide-Binding
Domains (NBDs) in a common MSD1-NBD1-MSD2-
NBD2 topology with intracellular N- and C-termini.
Each MSD is constituted by six transmembrane seg-
ments (TMs). Since this protein has not yet been crystal-
lized, and confident algorithm tools have been developed
to generate homology models based on reference tem-
plates [13], we generated two in silico models. Docking
analyses led us to identify several amino acid residues
potentially implicated in ABCC11 transport activity.
Additionally, molecular dynamics simulation revealed
for the first time conformational changes that would
occur during the transport process.Results and discussion
ABCC11 inward- and outward-facing models
The first model was based on the mouse mdr3 X-ray
structure [14] (Figure 1). Mouse mdr3 which shares 87%
homology with the human protein (ABCB1) was crystal-
lized in a nucleotide-free inward-facing conformation.
Our ABCC11 model adopts, as expected, an inward-
facing conformation where the assumed drug-binding
pocket is exposed to the intracellular space, allowing
drug binding before NBDs dimerization in the presence
of ATP (Figure 1). This conformation showed distant
NBDs and transmembrane helices bundled next to the






ctively adopt inward- and outward-facing conformations. ECL:
D: Membrane spanning domain; NBD: Nucleotide binding domain.
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tal structure from Staphylococcus aureus obtained in the
presence of ADP, and adopted an outward-facing con-
formation [15,16]. Compared to the first model, the con-
formation is logically reversed (Figure 1); the substrate
cavity is exposed to the extracellular space allowing re-
lease of bound substrates. In this conformation, ATP hy-
drolysis and ADP release are expected to bring the
transporter back to an inward-facing conformation. This
outward-facing conformation presents the TM helices
bundled next to the NBDs, closing the access from the
cytoplasmic side of transmembrane domains. The NBDs
are associated inside a dimer in which nucleotides are
sandwiched (Figure 2).
In both ABCC11 models, MSD helices extend from
membrane to cytoplasm, forming two intracellular loops
(ICLs) in each MSD. The first one is in contact with the
cis-NBD while the second one makes contacts with the
trans-NBD through its “hinge” sequence. By contrast to
mouse ABCB1 that showed similar hinge sequences
(RTVI in MSD1 and RTVV in MSD2), ABCC11 does
not display any conserved hinge sequences with KLIK in
MSD1 and SSIH in MSD2. Such a contact is supposed
to transduce conformational changes occurring from
NBD to MSD.
The ICLs show an interesting positively-charged re-
gion at the membrane leaflet (Figure 3) containing
several lysine and arginine residues. These positive
charges, just under the intracellular membrane side,
were likely involved in the drug transport process. This







Figure 2 The ADP molecules are sandwiched between the two
NBDs of ABCC11. ADP molecules (ball-shape) are inserted between
the Walker A sequence of one NBD (purple) and the signature
sequence of the other NBD (orange).the membrane and enhance its stability as described for
ABCC1 [17]. Indeed, Arg235, Lys988, Arg989 and
Arg1044 of ABCC11 respectively corresponded to
Lys396, Lys1141, Arg1142 and Arg1197 of ABCC1
[18-20] that were described to be functionally important
in organic anion transport. These residues might be in-
volved in ABCC11-mediated substrate transport. The
ABCC11 substrate-translocation site was essentially
positively charged, consistent with its ability to transport
anions. A similar observation was made for its ABCC5
homolog [21].
cGMP and 5FdUMP binding sites in ABCC11 models
Docking analysis on our ABCC11 models revealed
two putative binding pockets for cGMP and 5FdUMP
(Figure 4). An internal binding site (named pocket 1) in
ABCC11 was located next to the intracellular side of the
transmembrane region. It involved TM5, 7, 8, 9 and 12
(Figure 5). In this pocket, cGMP interacted with Ser880
in the inward-facing conformation of ABCC11, and with
Ser387, Lys439, Ser880, Thr888 and Asp931 in the
outward-facing model. In the inward-facing ABCC11
model, 5FdUMP was in interaction with Ser880 and
Glu1102, while in the outward-facing model, it
established only one hydrogen bond with Gly877.
An external ABCC11 binding pocket (named pocket
2) was located close to the extracellular space, and
formed by TM1, 6, 11 and 12 (Figure 5). In the inward-
facing ABCC11 model, cGMP could interact with
Glu194, Asn1082 and Trp826 while, in the outward-
facing conformation, only two hydrogen bonds were ob-
served with Thr1058 and Val1061, suggesting less inter-
actions. 5FdUMP could interact with Trp826, and
Asn1082, in the inward-facing model while Gly180,
Val1057 and Val1061 were involved in interactions
within the outward-facing model.
The local similarity does not exceed 24.3% between
binding sites of ABCC11 and the correspondent residues
in mABCB1. Between binding sites of ABCC11 and the
correspondent residues in SAV1866, similarity does not
go over 29.7%. The similarity figures are sufficient but
lower than those between ABCC11 and its ABCC4
homolog for example (until 43.2% of similarity). This
suggests that homology modeling permits the establish-
ment of models respecting the binding pocket structure
and thus the specificity of each protein for their sub-
strate spectrum. This point supports the fact that
docking experiments are reliable on these models of
ABCC11.
The identification of two potential binding pockets
strongly suggests that ligands can bind to two different
sites. Indeed, the QZ59-SSS cyclic peptide inhibitor
showed two different binding sites in mouse mdr3 X-ray
structure [14]. Based on docking analyses, MK571
Inward facing ABCC11 Outward facing ABCC11
Electrostatic potential
































Figure 4 cGMP and 5FdUMP binding to the two putative binding pockets. The best positions revealed vicinal residues (grey) and putative
hydrogen bonds (yellow) between substrates and residues.
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Figure 5 ABCC11 residues in a 5 Å diameter around bound ligand. a) Residues described in the putative binding pocket of ABCC5
(Ravna et al.). b) Residues described in the putative binding pocket of ABCC5 and conserved in ABCC11 (Ravna et al.). c) Residues described in
the binding pocket of ABCB1 (Aller et al.). d) Residues described in the binding pocket of ABCB1 and conserved in ABCC11 (Aller et al.). e)
Residues described in the putative binding pocket of ABCC4 (Ravna et al.). f) Residues described in the putative binding pocket of ABCC4 and
conserved in ABCC11 (Ravna et al.).
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ABCC11) also bound efficiently to both sites in silico
(data not shown). This observation was strongly sup-
ported by the fact that MK571 is a competitive inhibitor
of ABCC1-mediated LTC4 transport [22]. MK571 bind-
ing to one site would then not permit substrate trans-
port. Currently, no experimental data allows us to know
if ABCC11 substrates bind either simultaneously to both
sites, randomly to each site, or preferentially to the in-
ternal or external site.
ABCC11 residues potentially involved in substrate
transport
Because of their spatial position and putative interaction
with ligands, many of the residues reported in Figure 5might be important for ligand binding. Some residues
might directly interact with substrate while others
might be involved in allosteric modifications of ABCC11
conformation and affect the substrate binding affinity.
Some of the residues constituting ABCC11 pockets
corresponded to residues described for ABCC5 (Figure 5),
the closest ABCC member of ABCC11 [23]. Indeed, Ravna
et al. also described two putative binding pockets for
cGMP. The first binding pocket of ABCC11, involving
TM5, 7, 8, 9 and 12, would correspond to one of the
two binding pockets identified in ABCC5 (also involving
TM5, 7 and 8). The second ABCC11 binding pocket
was formed by TM1, 6, 11 and 12, similarly to the sec-
ond binding pocket described in ABCC5 [23]. ABCC11
Thr1058 (TM11) was located inside a binding site as
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and mouse ABCB1 (Tyr949 [14,24]). Some residues
(Ala176, Pro181, Leu815, Asn425) found in the binding
pockets are conserved between the two cGMP trans-
porters, suggesting their putative function in drug bind-
ing and/or transport.
In the same manner, several residues identified in
ABCC11 substrate pockets also correspond to residues
found in the substrate translocation chamber of ABCC4
outward facing model of Ravna et al. (Figure 5) [25].
Three of them are conserved between ABCC4 and
ABCC11 (ABCC11 residues Ala176, Pro181, Phe391).
The majority of those residues were located in binding
pockets of the outward facing model of ABCC11. As
listed in Figure 5, several ABCC11 residues identified
near the bound ligand also have equivalent residues in
the QZ59-binding pocket of mouse ABCB1. In addition,
Ser1090 corresponds to both ABCC1 Tyr1243 [26] and
ABCB1 Val982 [27] described to be important for the
transport function.
Among those residues, it is important to note that
Thr395, Phe432, Asn425, Leu815 and Thr1058 have
been described in ABCB1, ABCC4 and ABCC5 putative
substrate binding pockets. And finally, some residues
found in the drug-binding pockets have equivalents in
other ABC transporter that have been described to be
essential for transport function: Ile198 (ABCC1 Lys347
[18]), Phe433 (ABCC4 Phe 368 [28]), Lys439 (ABCC4
Glu374 [28]), Pro935 (ABCB1 Gly830 [29]), Ile1083
(ABCC1 Tyr1236 [26]), ABCB1 Leu975 [27]), Arg1050
(ABCC2 Arg1210 [30]), Ala1088 (ABCC1 Thr1241 [26])
and Arg1096 (ABCC2 Arg1257 [30]). Altogether, these
data confirm that our docking experiments were reliable
enough to identify ABCC11 drug binding pockets and
suggest that ABCB1, ABCC4, 5 and 11 would share a
comparative location for their substrate binding pockets.
Insight in the impact of Glycine 180 polymorphism
Gly180, found to be inside pocket 2, is prone to G602A
SNP (single nucleotide polymorphism) inducing the
Gly180Arg mutation which was correlated to earwax
type [31], and to colostrum and sweat secretion defaults
[32,33]. In addition, ABCC11-Arg180 mutant loses
transport capacity toward cGMP [31], in agreement with
Gly180 location in our model, in close proximity to
the ligand. In the inward-facing model, the Gly180
side-chain points toward phospholipids, while it points
toward cGMP in the outward-facing model. Thus, it
seems that Gly180 could be in close contact with ligand
only in the nucleotide-bound state where the drug-
substrate is ready to be released. The altered transport
of Gly180Arg-mutant ABCC11 can be explained by the
additional charge of arginine versus glycine. This may
modify side-chain localization and consequently thebinding site conformation. In the outward-facing state,
this positive charge could also promote interactions with
cGMP and decrease the efficiency of cGMP release into
the extracellular space. Toyoda et al. described a default
of N-glycosylation proposed to induce protein degrad-
ation. [34] Arg180 is thus likely modifying the proper
folding of ABCC11 rather than being directly involved
in substrate binding.
Conformational changes revealed by molecular dynamics
simulations
We hypothesize that the substrate first binds to the
intracellular side of transmembrane region and is then
translocated to the extracellular side (subsequent to con-
formational changes due to ATP binding and hydrolysis).
Molecular dynamics simulation was thus performed
with the ABCC11 inward facing model inserted into a
phospholipid bilayer membrane (Figure 6A). The calcu-
lated 1D root mean square deviation (RMSD, based on
align seed residue and list distance parameters) on all
heavy atoms is weak and evaluated at 3.6944 Å between
the frame 100 to frame 1000 (Figure 6B). The 2D-RMSD
allowed identifying four principals steady states during
these 10 ns dynamics simulation (Figure 6C). Length of
the molecular dynamics simulation is limited by the
presence of phospholipid membrane and size of the pro-
tein (190 KDa). According to the molecular dynamics
simulation, the inward-facing model gently changed its
conformation. Residues of the internal pocket 1 tended to
move closer to each other, suggesting a closing of the bot-
tom part of ABCC11, while residues of the external pocket
2 tended to move away from each other, suggesting by
contrast an opening of the top part of ABCC11 (Figure 7).
These findings strongly suggested that substrate could
enter the transporter from cytoplasm to bind into opened
pocket 1 while pocket 2 is closed.
In the literature, Chen et al. described the existence of
two different binding sites in ABCC11 for DHEAS and
E2-17βG [2]. They proposed that low concentrations of
DHEAS had a stimulatory effect on ABCC11 transport
of E2-17βG because it would bind to a distinct site,
whereas, at high concentration, DHEAS would rather
compete with E2-17βG binding at the transport site.
Moreover, they observed that E2-17βG exerted an
inhibitory effect on DHEAS transport by ABCC11. By
consequence, the interaction between E2-17βG and
DHEAS is not reciprocal, and do not respond to co-
transport situation but rather to the existence of two
binding sites. Nevertheless, in the present study, we
studied the transport of 5FdUMP and GMPc molecules
that are structurally completely different. We suggested
that these nucleotide derivatives make different interac-
tions with the residues of ABCC11 binding sites or bind
distinct binding sites.
BEFORE DYNAMICS SIMULATION AFTER DYNAMICS SIMULATION
Figure 7 Molecular dynamics simulation revealed the closing of ABCC11 pocket 1, concomitant with pocket 2 opening. In order to see
their conformation changes, some residues of each pocket are shown in red ball shape within the entire ABCC11 protein. ABCC11 inward-facing
















Figure 6 Structure of the ABCC11 complex for molecular dynamics simulation and RMSD calculations. (A) The inward facing model of
ABCC11 was inserted in a phospholipid bilayer membrane surrounded by solvent. (B) 1D-RMSD of the ABCC11 complex during the dynamics
simulation before (grey) and after (black) reaching equilibrium state. (C) 2D-RMSD calculations (X and Y axes represent the frames), carried out on
500 conformations selected with a stride of 2 from the 1000 produced during the indicated time simulation. The four steady-state conformations
of each simulation are numbered. Warm colors (yellow and white) revealed steady state was reached.
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tially simulate the transport cycle of ABCC11. Our data
suggested that substrate would cross the protein to bind
to pocket 2 (Figure 7). Subsequent conformational
changes would open pocket 2 to allow substrate to reach
the extracellular space and strongly support the presence
of multiple allosteric substrate binding sites in ABCC11
protein. The presence of possible allosteric interactionsFigure 8 ABCC11 and mABCB1 sequence alignment.was supported by Van Aubel’s study [12]. They sug-
gested that ABCC4 transports urate through a positive,
cooperative allosteric interaction. Urate changed cGMP
transport from an allosteric to a single binding site. Fur-
thermore, they showed that cAMP and cGMP could be
simultaneously transported with urate by ABCC4, under
saturated conditions, suggesting multiple binding sites.
At present, these experimental data are consistent with
Honorat et al. BMC Structural Biology 2013, 13:7 Page 9 of 12
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would bind to a first site and that conformation changes
would allow binding to a second site before release and
fully explained the 5FdUMP transport process.
Conclusions
Thanks to homology modeling, we have provided two
ABCC11 models corresponding to different catalytic states.Figure 9 ABCC11 and Sav1866 sequence alignment.We could identify two putative binding pockets for sub-
strates in both models, and recognized several residues
that could interact with a bound substrate. These results
constitute a useful tool for future biochemical experiments
where the specific role of the identified residues could be
study in vitro by site-directed mutagenesis experiments
and transport activity characterization in cell expressing
ABCC11. Molecular dynamics simulation strongly helped
5FdUMPcGMP
Figure 10 Structures of cGMP and 5FdUMP.
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ism of secretion. In addition to constitute a complementary
tool in identifying the residues’ importance during trans-
port process, they revealed new insights in ABC trans-
porter mechanism of efflux.
Methods
Prediction of ABCC11 transmembrane domain (TM)
Data were compiled from TM predictions of 6 independ-
ent software analyses: HMMTOP, SOSUI, TMHMM ser-
ver, TMPRED, TOPRED and PredictProtein. A score was
obtained according to the number of predictions for each
residue to be located in plasma membrane (Additional
file 1). Considering the scale from 1 to 6, residues with a
score of at least 4 were considered as belonging to the
TM. Nevertheless, although the score of TM12 was only
predicted by 3 algorithms, comparison with other ABCC
topologies led us to validate this TM12 position.
Sequence alignments
Primary sequences of human ABCC11 (Q96J66), mouse
ABCB1 (P21447) and S. aureus Sav1866 (Q99T13) were
downloaded from the Swiss-prot database. Multiple se-
quence alignment of amino acid sequences was carried
out using ClustalW 2.0. Taking in account TM predic-
tions automatically carried out by softwares, sequence
alignment was manually refined, according residue prop-
erties (polarity, charge, hydrophobicity) and finally vali-
dated to align ABCC11 TM with reference templates
(ABCB1 in Figure 8 and Sav1866 in Figure 9). After
alignment refinement, the percentage of sequence iden-
tity between ABCC11 and mABCB1 was 15.91% while
the similarity rose to 29.18% (data obtained from the
sequence identity and similarity server, SIAS). With
Sav1866, the percentage of sequence identity was 15.93%
and the percentage of similarity was 29.1%.
Selection of X-ray structures and model building
PDB files generated from crystal structures were
downloaded from the SWISS-MODEL template library:
mouse ABCB1 (PDB code 3G5U) and Sav1866 from
Staphylococcus aureus (PDB code 2HYD).
Since Sav1866 is a half-transporter (only one MSD and
one NBD) and since mouse ABCB1 template was pub-
lished in two-separate peptides (MSD1-NBD1 and MSD2-
NBD2 domains without the flexible linker from residue
627 to 683), the ABCC11 model was generated as two
halves: MSD1-NBD1 and MSD2-NBD2 halves. Sequence
alignments were submitted to the SWISS-MODEL work-
space to generate tri-dimensional models of ABCC11.
Minimizations (> 10000 steps with the conjugated gradi-
ent algorithm) were carried out with the Sybyl-X 1.1 soft-
ware package, elaborated by the Tripos company. We
applied the Tripos force field with the Gasteiger-Marsillipartial charges and a dielectric constant of 80 to simulate
an implicit water phase (the dielectric constant of water is
20.10 at 20°C). No restrains was applied to our models.
This step principally refines and corrects the positions of
residue side chains.
Ligand docking
Docking was performed with the Sybyl-X 1.1 software to
localize putative binding sites for substrates [35]. Docking
simulations were computed using de Surflex-Dock module
of the Sybyl X1.1 molecular modeling suite. Charges of
molecules were computed using Gasteiger-marsilli algo-
rithm and the option of the docking module were set. The
maximum of conformation per fragment was set to 100,
to increase possibility of different conformation and the
maximal number of rotable bond set to 200. This great
number of conformations is allowed because the databank
of molecules is small. The following options were selected:
soft grid treatment, pre-docking and post-docking minimi-
zations and the molecule fragmentation. Chemscore,
D_score, G_score and PMF_score were selected for scor-
ing function. The structure was not relaxed during the
scoring calculation.
Independent docking runs were carried out for each
ligand (cGMP and 5FdUMP, structures in Figure 10). A
volume including almost all the entire MSD fraction of
ABCC11 was defined in order to identify binding sites
either in the transmembrane part or at the membrane
leaflet (extracellular or intracellular side). Two main
binding pockets were described in each model, for each
ligand. In order to refine substrate position, docking
runs were performed again by only selecting the amino
acid residues constituting those pockets.
Molecular dynamics simulation
The model of the ABCC11 protein was loaded in VMD
1.8.3 program. A POPC phospholipid bilayer was added
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tein was inserted in the membrane according to known
area [36,37]. All POPC in contact with the protein were
removed and the resulting model was inserted in a
parallelepipedic TIP3P solvent box with the add solv-
ation box module of VMD 1.8.3 software. A distance of
15 Å was set between the surfaces of the protein to the
limit of the solvent box; the resulting models have a
membrane size of 94 Å × 97 Å with a height of 135 Å.
Conditions were computed to reach neutral charges
before adding sodium and chloride to concentrations
corresponding to physiological conditions. The model
was minimized with the NaMD 2.8 b1 software for 1000
steps before the molecular dynamics simulations [38]. It
was computed on a 144 xeon core CPU cluster super-
computer (SGI Altix).
Simulations were carried out at constant temperature
(300 K) and pressure (1 atm) and by implementing the
widely used CHARMM 27 force fields. The time step
was set at 1 fs and Langevin dynamics was performed
with a target piston pressure of 1.01325 bar and a
damping coefficient of 5 ps-1. There is no coupling of
the Langevin temperature with hydrogen. The PME al-
gorithms were applied with a grid extended by 10 Å
from the PBC size [39]. The electrostatic cut-off was set at
14 Å. A conformation was sampled every 10 ps. As the
solvent was described, the dielectric constant was set at 1.
To identify steady conformations, 2D-RMSD calcula-
tions were carried out on 500 conformations selected,
with a stride of 2, from the 1000 conformations pro-
duced during the 10-ns simulation. The equilibrium
state was reached around 1 ns for studied model, and is
longer than usual as it includes phospholipid membrane.
Additional file
Additional file 1: Predictions of amino acid residues located inside
the membrane. TransMembrane segments (TMs) are numbered from 1
to 12. The positions of the first and last amino acid residues are indicated
in the first column. The second line reports the prediction score obtained
by independent softwares: HMMTOP, SOSUI, TMHMM server, TMPRED,
TOPRED and PredictProtein.
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